Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glargine + Exenatide vs Aspart 30 in T2DM
NCT02467920Phase 4Completed
- Sponsor
- Huazhong University of Science and Technology
- Start
- Aug 2015
- Primary completion
- Dec 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine, exenatide in type 2 diabetes mellitus (T2DM), sponsored by Huazhong University of Science and Technology. Started Aug 2015; status: completed.
02
Drugs
insulin glargineexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02467920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467920.